Induction of apoptotic cell death by modulating the oncogenic signaling pathways, including JNK, Bax and Bcl-2, and PI3K/Akt and MAPK/ERK, has been suggested as the potential underlying mechanism of the anti-cancer effects of simvastatin [21–23]. The gene discussed is BCL2; the disease is cancer.